Our history

Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland

Boan Grants NKF Rights to Commercialize BA6101 and BA1102 in US

Five new products included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List

Boan’s aflibercept intravitreous injection Boyoujing® Approved for Marketing in China

Boan’s Dulaglutide Injection Approved for Marketing in China

Luye Pharma, Boan Biotech, and HKUST cooperate to empower cutting-edge drug R&D and drive groundbreaking innovations

Luye Pharma's New Schizophrenia Drug ERZOFRI® Makes Its Debut at APA Conference in the U.S.

Rotigotine Transdermal Patch was approved in UK

Rivastigmine Transdermal Patch was approved in Japan

Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) was approved for marketing in China

Jinyouping(rotigotine microspheres for injection) was approved for marketing in China

Meibirui(paliperidone palmitate injection) was approved for marketing in China

Boluojia (denosumab injection 120mg) was approved for marketing in China

ZEPZELCA®(Lurbinectedin) has been approved in Hong Kong and Macao for the treatment of relapsed small cell lung cancer

Luye Life Sciences attended SCO Conference on Traditional Medicine Industry

Toronto Private Hospital team was acknowledged as finalists in the category of Excellence in Large Business at the iconic Business Hunter Awards (2023).

Robina Private Hospital Won 2023 Awards for Excellence

WPU signed an MoU with AstraZeneca Brazil and Brazilian Herbarium, to bring Xuezhikang to the Brazilian market

Luye Life Sciences Launched Innovative Vaccine and Biotechnology Center Project in Uzbekistan

Luye Pharma won the "2023 Most Branded Listed Company" award.

The first Canberra-based mental health facility - Deakin Private Hospital was opened

Luye Pharma and Boan Biotech won the 2022 Yantai Biopharmaceutical Industry High Quality Development and Innovation Award

Luye Diagnostics（China）released China’s first non-invasive diagnostic kits for H. pylori and its DRMs

Study tour to Australia on meatal health led by Mindfront Academy was concluded successfully, romoting academic exchange

The world’s only Goserelin Microspheres for Injection (Baituowei) received marketing approval in China for the treatment of prostate cancer and breast cancer

Rykindo® (risperidone) for extended-release injectable suspension received marketing approval in the U.S.，making it the first FDA approved new drug in the CNS therapeutic field developed from China

Boan Biotech was listed on the main board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company

Boyoubei® received marketing approval in China for the treatment of osteoporosis. It is the first denosumab injection developed locally in China.

Ruoxinlin®(Toludesvenlafaxine Hydrochloride Extended-release Tablets), China’s first class 1 innovative chemical drug for the treatment of major depressive disorder, received marketing approval in China

In February 2022, Mindfront opened a high-ened hospital in Xi’an to serve more patients suffering from mental health problems

3 new Mindfront institutions were opened in Shanghai, Xi'an and Shenzhen

Rivastigmine Multi-Day Transdermal Patch received marketing approval in several European countries, optimizing the treatment regimen for Alzheimer’s with an upgraded formulation

Bevacizumab Injection received marketing authorization in China, becoming the 1st biologic developed by Boan Biotech to enter the market

Rykindo® Approved in China. It's Luye's independently developed Risperidone Microspheres for Injection for the treatment of acute and chronic schizophrenia.

The once-daily Rivastigmine Transdermal Patch received market approval in China, to help improve safe treatment for patients with Alzheimer's disease

Acquired Boan Biotech, accelerating development in the field of biopharmaceuticals

Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from the new drug

Luye Medical Group establishes mental health division in China.

Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets

The Group creates a new brand system,
marking a new era in building an international life sciences group

Luye Pharma acquired the business of Seroquel
in 51 Countries and Regions from AstraZeneca

Luye Group officially changed its name to
"Luye Life Sciences Group"

Boston R&D Center was put into operation,
laying a solid technical foundation through collaboration
on new platforms and projects,
to help ensure the sustainable pipeline development.

Luye Pharma acquired Europe's leading
transdermal drug delivery Business.

Luye Medical acquired Healthe Care,
Australia's third largest private hospital group.
The international development has taken a solid step.

Luye Pharma's self-developed microsphere product
LY03004 completed all registered clinical research in the U.S.

Several innovative preparations and new drugs were
registered in the U.S. for clinical research.

The solid preparation production line of Luye Pharma passed
the EU GMP inspection.

Luye Pharma acquired Sichuan Baoguang Pharmaceutical,
to strengthen the endocrine and metabolic system product line.

Luye Pharma acquired Nanjing Kanghai,
Nanjing Sike and Beijing Peking University WBL,
strengthening the oncology and cardiovascular product line.

Luye Pharma first landed in the international
capital market, listed in Singapore.

Established the "Golden Leaf medal” system to recognize
the Luyers who work and grew up with the company.

The Luye Pharma R&D Center was established.

Luye Pharma Intellectual Property Department and
the International Cooperation Department were established.

The revenue of Luye Pharma exceeded RMB 100 million.

Luye Pharma founded its predecessors.